Par Pharmaceutical Companies, Inc. (NYSE:PRX)
| CAPS Rating |
|
|---|---|
| Open | $36.70 |
| Previous Close | $37.05 |
| Daily Range | $36.15 - $36.70 |
| 52-Week Range | $24.85 - $38.85 |
| Market Cap | $1.33B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 186,060 |
| Average Daily Volume | 0 |
PRX
VS S&P 500 (SPY)
How do you think PRX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PRX News and Commentary
- Get These 5 Stocks While They're Hot - Investment Ideas – NASDAQ
- Lawsuit Alleges Walgreen, Par Pharma Overcharged For Generics – SmartMoney
- Pozen Inks $75 Million Royalty Deal for Treximet – The Motley Fool
- Par Pharmaceutical Earnings Preview – The Motley Fool
- Why Par Pharmaceutical May Be About to Take Off – The Motley Fool
- FDA OKs Generics Of Zyprexa For Bipolar Disorder, Schizoprenia – SmartMoney
- Stocks Rebound, Trade Higher Amid Mixed Slate of Earnings; China Data Weighs – NASDAQ
- Mid-Day Update: Stocks Shift Higher After Mixed Start; China, Earnings Weigh – NASDAQ
- Magic Formula Investing Weekly Roundup 9/10/2011 – Blog at The Motley Fool
- Will AstraZeneca Disappoint Analysts Next Quarter? – The Motley Fool
- Generics on the Rise: A Big Threat to Big Pharma? – NASDAQ
- Why the Future Looks Bright for Auxilium Pharmaceuticals – The Motley Fool
- Somaxon Discloses Patent-Infringement Suit Against Mylan – SmartMoney
- Why the Street Should Love GlaxoSmithKline's Earnings – The Motley Fool
- Somaxon Files Lawsuit Against Par Pharma Involving Generic Silenor – SmartMoney
- Par Pharmaceuticals - Buried in the Generic Drugs Battlefield – Blog at The Motley Fool
- UPDATE: Novartis CEO Warns On Misconduct After Executive Firings – SmartMoney
- Top Pharma Stocks That Hedge Funds Love – SeekingAlpha
- Pozen Wins Injunction Blocking Generic Migraine Drug – The Motley Fool
- Pozen: Injunction Stops Par From Selling Generic Of Pozen Drug – SmartMoney
RSS Headlines
Fool UK
